 BEDMER, N.J.--BUSINESS WIRE--TYME Technologies, Inc. TYME or the Company NASDAQ: TYME, an emerging biotechnology company developing cancer metabolism-based therapies CMBTsTM, today announced that the first patient has been dosed in the Phase II OASIS trial in patients with metastatic hormone receptor positive, human epidermal growth factor receptor 2 negative HRHER2- breast cancer who previously received a CDK46 inhibitor regimen being conducted by Georgetown University N 